Fulcrum Therapeutics, Inc.
FULC
$6.63
$0.111.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.03% | -6.56% | 23.64% | -139.16% | 306.21% |
| Total Depreciation and Amortization | -2.55% | -4.34% | 0.00% | -1.86% | -21.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.08% | 48.04% | -42.51% | -16.98% | 16.52% |
| Change in Net Operating Assets | 701.79% | 89.35% | -410.73% | -327.08% | 94.17% |
| Cash from Operations | 9.42% | 8.97% | 12.12% | -132.38% | 332.95% |
| Capital Expenditure | -- | -- | -1,115.79% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,901.54% | -131.19% | -42.98% | 134.93% | -132.78% |
| Cash from Investing | 1,893.18% | -134.38% | -48.05% | 134.78% | -132.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -86.93% | 68.44% | -77.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -86.93% | 68.44% | -77.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.58% | -11.21% | -2.35% | -130.12% | 222.65% |